GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSNKY) » Definitions » 3-Year EBITDA Growth Rate

Daiichinkyo Co (Daiichinkyo Co) 3-Year EBITDA Growth Rate

: 0.80% (As of Dec. 2023)
View and export this data going back to 2008. Start your Free Trial

Daiichinkyo Co's EBITDA per Share for the three months ended in Dec. 2023 was $0.45.

During the past 12 months, Daiichinkyo Co's average EBITDA Per Share Growth Rate was 87.50% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 0.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 5.80% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Daiichinkyo Co was 13.50% per year. The lowest was -14.30% per year. And the median was 0.60% per year.

Competitive Comparison

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daiichinkyo Co 3-Year EBITDA Growth Rate Distribution

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's 3-Year EBITDA Growth Rate falls into.


Daiichinkyo Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Daiichinkyo Co  (OTCPK:DSNKY) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Daiichinkyo Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co (Daiichinkyo Co) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSNKY) » Definitions » 3-Year EBITDA Growth Rate
Comparable Companies
TSE:4519 TSE:4503 TSE:4578 TSE:4151 TSE:4528 TSE:4536 TSE:4552 TSE:4882 LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN BMY GILD
Traded in Other Exchanges
DSKYF:USA 4568:Japan D4S:Germany
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Website
https://www.daiichisankyo.com
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.